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Evaluate COTS packing materials for 
Radiation Shielding and Moisture 
Protection of three susceptible medications 
from Space Flight Medication Kit (SFMK)
Aim
 As NASA moved forward with exploration and 
longer duration missions, pharmaceutical use in 
space has increased. 
 During the first 33 space shuttle missions, crew 
members took more than 500 individual doses of 31 
different medications (Tietze and Putcha, 1994).
 Anecdotal reports from crew members described 
medications as generally “well tolerated” and 
“effective”.  However, reports of increased 
medication doses and discrepancies in ground vs. 
flight efficacy were reported.
 One of the possible causes for reduced potency or 
altered bioavailability can be changes in chemical 
and/or physical parameters of pharmaceutical 
stability .
Introduction
 Technology Development Goal 
–
Blister packs and FMD with special 
shielding material for protection 
against radiation, thermal 
degradation, oxidation, hydrolysis 
and shear effects
 COTS Shielding Material –
Aluminum coated Mylar sheathing 
material coated with 
multifunctional nanocomposities 
based on polyethylene with 
dispersed boron-rich nanophases
Background
 Stability of dosage forms in the 
pharmaceutical payload aboard space 
missions
Results: Some medications are more sensitive than 
others to conditions of space flight.
Augmentin® tablets – sensitive to light and humidity
Bactrim® tablets – sensitive to light
 Promethazine tablets – sensitive to light
Related Research

Test Oliver-Tolas TPL-1475 and TPF-0599B 
bags for protection of medications against 
ionizing radiation and moisture effects
 Augmentin®: Amoxicillin/Clavulanate 
combination antibiotic
 Bactrim® - Sulfamethoxazole/trimethoprim 
combination antibiotic
 Phenergan® - promethazine antihistamine
Objective
 Radiation testing: 
 Packed 8 bags each of Oliver-Tolas TPC-1475(Clear) and Oliver-
Tolas TPF-0599B (Foil) material containing 9 tablets in each bag 
of one of the three medications – total of 24 bags of 3 
medications.  Of the 8 bags, 
 2 bags served as control (no irradiation) .
 2 bags of each medication were irradiated for different time 
intervals with 14.6 rad/min using Hopwell BX35 PS137 at 35 cm 
distance in a cardboard box  to achieve 0.1 Gy, 1 Gy and 10 Gy of 
cumulative dose.
 Humidity testing:
 Augmentin® tablets (9) were packaged in 4 TPC-1475 and 4 TPF-
0599B bags. 
 2 bags served as control and 2 were stored at 25ºC & 75%RH for 
6 days for accelerated humidity testing. 
 Chemical content of all medications was analyzed using Waters 
UPLC system.  All analyses were done according to standard 
United States Pharmacopeia (USP) methods verified and 
validated in the JSC Pharmaceutical Analysis Lab.
Methods
Active Amoxicillin Clavulanate
Condition Content (%) SD Content (%) SD 
0 Time 107.9 0.77 98.4 0.35
Control 106.7 1.14 98.6 1.32
0.1Gy Clear 106.1 1.19 98.6 1.04
0.1Gy Foil 106.4 1.50 96.5 0.31
1Gy Clear 105.1 1.59 97.4 1.99
1Gy Foil 105.4 0.96 96.3 0.92
10 Gy Clear 106.6 0.43 96.5 0.44
10 Gy Foil 105.8 0.92 96.7 1.38
25oC&75%RH 
Clear
106.4 0.60 96.5 1.43




Condition Content (%) SD Content (%) SD 
0 Time 101.5 0.64 100.5 1.05
Control 100.4 0.74 99.9 1.22
0.1Gy Clear 101.2 1.02 100.2 1.48
0.1Gy Foil 99.9 1.45 99.7 1.25
1Gy Clear 100.0 1.01 99.7 0.91
1Gy Foil 99.7 0.66 99.2 0.69
10 Gy Clear 99.4 0.78 98.6 1.29
10 Gy Foil 98.6 1.40 98.0 1.99
Bactrim® Tablets
Condition Content (%) SD 
0 Time 98.8 0.38
Control 98.3 0.83
0.1Gy Clear 95.9 0.74
0.1Gy Foil 96.0 0.58
1Gy Clear 96.0 0.78
1Gy Foil 95.8 1.08
10 Gy Clear 95.8 0.50
10 Gy Foil 95.3 0.54
Promethazine Tablets
 No significant difference in content between control and  
irradiated samples was noticed for Bactrim® and 
Augmentin® tablets suggesting both COTS materials may 
offer protection against  radiation (γ).
 Preliminary results from this study are insufficient to 
determine effectiveness of COTS materials for Phenergan® 
tablets.
Discussion
 RH test results indicate no 
significant difference in 
content between control and 
test condition for 
Augmentin® tablets (6 days 
of storage in high RH of 
75%). 
Condition     Time                   % Content
(d)     Amoxicillin    Clavulanic Acid 
25ºC                 0         110.5                      95.7
75%RH           1         107.0                      94.2
SFMK              3         100.9                      88.1
Pill Bottle        7         99.4                    70.6
25ºC                 0         110.5                      95.7
75%RH           1         108.1                      94.7
Commercial    3         105.2                      93.2
Package          7          104.0                      89.0
Experimental Artifacts
 Compromised experimental design
 Insufficient  samples and controls
 Inadequate technology streamlining and 
validation procedures
 Oliver-Tolas TPL-1475 and TPF-0599B bags 
materials may be suitable for protection of 
clavulanate against humidity.
 Both materials may have characteristics 
suitable for protection against  ionizing 
radiation and high RH and may be 
candidates for further testing separately 
and in combination. 
Conclusion
 Compare both materials for relative efficiency 
separately and in combination
 Investigate Nanoparticle coating technology for 
environmental protection (Rice Nanotechnology 
Center)
 Identify and develop FMD design options with the 
materials – unit dose pop-up packing (COTS 
redesign)
 special design multi dose dispenser bags (COTS)
 Investigate kit design options using the new 
materials for Space hardy storage and dispensing
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